RTP Mobile Logo
Select Publications

Bishop MR et al. Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma: Analysis of the Phase III Belinda study. ASH 2021;Abstract LBA-6.

Budde LE et al. Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: Pivotal results from a Phase I/II study. ASH 2021;Abstract 127.

Carlo-Stella C et al. Planned interim analysis of a Phase 2 study of loncastuximab tesirine plus ibrutinib in patients with advanced diffuse large B-cell lymphoma (LOTIS-3). ASH 2021;Abstract 54.

Chavez JC et al. The combination of umbralisib plus ublituximab is active in patients with relapsed or refractory marginal zone lymphoma (MZL): Results from the Phase 2 global Unity-NHL Trial. ASH 2021;Abstract 45.

Dave SS et al. Molecular and genetic characterization of tumor samples from patients with relapsed or refractory follicular lymphoma identifies factors influencing response to tazemetostat. ASH 2021;Abstract 1183.

Desai S et al. Novel salvage regimens lead to better response and survival in relapsed refractory classic Hodgkin lymphoma after autologous stem cell transplant. ASH 2021;Abstract 878.

Di M et al. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: A population-based analysis. ASH 2021;Abstract 182.

Kamdar M et al. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Results from the randomized phase 3 Transform study. ASH 2021;Abstract 91.

Kumar A et al. Preliminary safety and efficacy from a multicenter, investigator-initiated Phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen). ASH 2021;Abstract 3540.

Locke FL et al. Primary analysis of ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma. ASH 2021;Abstract 2.

Lynch RC et al. Efficacy and safety of parsaclisib in patients with relapsed or refractory follicular lymphoma: Primary analysis from a phase 2 study (CITADEL-203). ASH 2021;Abstract 813.

Morschhauser F et al. Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) follicular lymphoma (FL). ASH 2021;Abstract 128.

Neelapu SS et al. Long-term follow-up analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma. ASH 2021;Abstract 93.

Neelapu SS et al. Primary analysis of ZUMA-12: A phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). ASH 2021;Abstract 739.

Nowakowski GS et al. Tafasitamab plus lenalidomide versus pola‑BR, R2, and CAR-T: Comparison of outcomes from RE-MIND2, an observational retrospective cohort study in relapsed or refractory diffuse large B-cell lymphoma. ASH 2021;Abstract 183.

Phillips T et al. An oncology simulation model to estimate 10-year progression-free survival and stem cell transplantation for frontline, stage III or IV classical Hodgkin lymphoma based on the 5-year update of the ECHELON-1 Trial: A United States Perspective. ASH 2021;Abstract 2440.

Phillips T et al. Efficacy and safety of parsaclisib in patients with relapsed or refractory marginal zone lymphoma: Primary analysis from a phase 2 study (CITADEL-204). ASH 2021;Abstract 44.

Thieblemont C et al. Efficacy of tisagenlecleucel in adult patients (pts) with high-risk relapsed/refractory follicular lymphoma (R/R FL): Subgroup analysis of the Phase II ELARA study. ASH 2021;Abstract 131.

Tilly H et al. The POLARIX Study: Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma. ASH 2021;Abstract LBA-1.

Wang M et al. Ibrutinib plus rituximab and venetoclax (IRV) followed by risk-stratified observation or short course R-hypercvad/MTX in young patients with previously untreated mantle cell lymphoma – Phase-II Window-2 clinical trial. ASH 2021;Abstract 3525.

Wang ML et al. Pirtobrutinib, A highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the Phase 1/2 BRUIN study. ASH 2021;Abstract 381.

Wang Y et al. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: Real world experience from the US Lymphoma CAR T Consortium. ASH 2021;Abstract 744.